获得性放射抵抗乳腺癌细胞系的建立与表征
研究通过每周递增剂量照射MDA-MB-231、MCF-7和ZR-751亲本细胞建立放射抵抗细胞系,经增殖和集落形成实验确认放射抵抗,放射抵抗细胞迁移侵袭增强并呈现上皮间质转化证据。MCF-7和ZR-751放射抵抗细胞ERα和PgR表达丢失、EGFR表达增加,转录组数据提示亚型从亲本Luminal A变为HER2过表达(MCF-7 RR)和正常样(ZR-751 RR)。
要点
- 每周递增剂量照射成功建立三株放射抵抗乳腺癌细胞系并经增殖和集落形成实验确认。
- 放射抵抗细胞迁移侵袭增强并伴上皮间质转化证据。
- MCF-7和ZR-751放射抵抗细胞ERα和PgR表达丢失、EGFR表达增加且亚型分类改变。
核心结论
- 这是首项通过遗传和表型分析广泛描述三株新型放射抵抗乳腺癌细胞系建立与表征的研究。
- ER+(MCF-7和ZR-751)模型亲本细胞与放射抵抗衍生细胞间鉴定的变化多于ER-细胞系(MDA-MB-231)模型。
- 鉴定出多种可能相互关联、可能促成获得性放射抵抗发生的机制。
研究设计与样本
- 将MDA-MB-231、MCF-7和ZR-751亲本细胞暴露于每周递增剂量照射以建立放射抵抗细胞系。
- 通过增殖和集落形成实验评估放射抵抗的发生。
- 表型表征包括迁移和侵袭实验及免疫组织化学。
- 生成转录组数据用于初步假设生成,涉及通路聚焦分析。
主要发现
- 增殖和集落形成实验确认了放射抵抗。
- 放射抵抗细胞迁移和侵袭增强,并有上皮间质转化证据。
- MCF-7和ZR-751细胞系获得放射抵抗后ERα和PgR表达丢失、EGFR表达增加。
- 基于转录组数据,MCF-7放射抵抗细胞亚型从亲本Luminal A变为HER2过表达,ZR-751放射抵抗细胞变为正常样。
- 源自ER+细胞的放射抵抗细胞系显示从ER向EGFR信号通路转变,MAPK和PI3K活性增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiotherapy plays an important role in the multimodal treatment of breast cancer. The response of a breast tumour to radiation depends not only on its innate radiosensitivity but also on tumour repopulation by cells that have developed radioresistance. Development of effective cancer treatments will require further molecular dissection of the processes that contribute to resistance. METHODS: Radioresistant cell lines were established by exposing MDA-MB-231, MCF-7 and ZR-751 parental cells to increasing weekly doses of radiation. The development of radioresistance was evaluated through proliferation and colony formation assays. Phenotypic characterisation included migration and invasion assays and immunohistochemistry. Transcriptomic data were also generated for preliminary hypothesis generation involving pathway-focused analyses. RESULTS: Proliferation and colony formation assays confirmed radioresistance. Radioresistant cells exhibited enhanced migration and invasion, with evidence of epithelial-to-mesenchymal-transition. Significantly, acquisition of radioresistance in MCF-7 and ZR-751 cell lines resulted in a loss of expression of both ERα and PgR and an increase in EGFR expression; based on transcriptomic data they changed subtype classification from their parental luminal A to HER2-overexpressing (MCF-7 RR) and normal-like (ZR-751 RR) subtypes, indicating the extent of phenotypic changes and cellular plasticity involved in this process. Radioresistant cell lines derived from ER+ cells also showed a shift from ER to EGFR signalling pathways with increased MAPK and PI3K activity. CONCLUSIONS: This is the first study to date that extensively describes the development and characterisation of three novel radioresistant breast cancer cell lines through both genetic and phenotypic analysis. More changes were identified between parental cells and their radioresistant derivatives in the ER+ (MCF-7 and ZR-751) compared with the ER- cell line (MDA-MB-231) model; however, multiple and likely interrelated mechanisms were identified that may contribute to the development of acquired resistance to radiotherapy.
引用
- Gray M, Turnbull AK, Ward C, et al. Development and characterisation of acquired radioresistant breast cancer cell lines. Radiat Oncol. 2019. PMID: 30987655. doi:10.1186/s13014-019-1268-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。